On April 17, 2018, FDA is conducting a public meeting on Patient Focused Drug Development (PFDD) for Opioid Use Disorder (OUD). This meeting will provide FDA the opportunity to better understand the patient perspective on the impacts of OUD and on treatment approaches for OUD.
FDA is interested in learning patients’ perspectives on OUD, including the effects on their health and well-being that have the greatest impact on daily life, their experience using prescription medical treatments and other treatments or therapies for OUD, and challenges or barriers to accessing or using medical treatments for OUD. This meeting is a part of FDA’s ongoing work aimed at reducing the impact of opioid abuse and addiction.
This website will be updated as meeting materials are developed.
Date: April 17, 2018
Time: 10:00 a.m. - 4:00 p.m.
Location: FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503A (Great Room)
Silver Spring, MD 20993
(Information about arrival to FDA’s White Oak campus)
Registration:To register for this meeting, visit: Public Meeting on Patient-Focused Drug Development for
Opioid Use Disorder
We recommend early registration for the meeting
- CDER Patient Focused Drug Development
- Enhancing Benefit-Risk Assessment in Regulatory Decision-Making